ASTANA, Kazakhstan, May 24, 2013 /PRNewswire/ –

Panel Session “Sustainable Industry Development Through Infrastructure Development.” Kazakhstan’s Vice Minister of Industry and New Technologies Kanysh Tuleushin: “Thanks to our economic achievements in the years since independence, Kazakhstan has all  the prerequisites to enter a new level of economic development”. Memorandum of Cooperation between the United Nations World Tourism Organization and the Ministry of Industry and New Technologies of Kazakhstan was signed.

     (Logo: http://photos.prnewswire.com/prnh/20121112/573878 )

Panel Session “Fundamentals of the Transition to a Green Civilization.” In the development of a new green civilization these first steps need to be taken: Building a bridge between the economy, the environment and the social needs of a country. Economic leadership to ensure that industrialization does not reduce life expectancy – a shameful byproduct of industrial civilization.

Panel Session “Developing a System for Producing Effective Political Managers in the Modernization of Public Administration.” Chairman of the Agency for Civil Service Alikhan Baimenov: “For Kazakhstan, in accordance with Nursultan Nazarbayev’s Development Strategy 2020, which provides for the next stage of civil service reform, embracing the best international practices is very important to. In return, we are ready to share Kazakhstan’s model of public service, which has been praised by international experts.”

The II World Economic Forum of Youth “Generation Global: Youth Initiatives for Sustainable Economic Development.” Awarding of the Nobel Laureates Club’s Youth Grant of AstanaThe five-million-tenge prize went to Mariam Voskanyan of Yerevan, Armenia.

Panel Session “Kazakhstan‘s Nobel-Family Heritage.” An Oil and Gas Museum, a Nobel-Family Heritage Fund and a Nobel Club will be established in Kazakhstan.

Panel Session EXPO 2017 “Will the Energy of the Future Change Our Lives?“. “The bridge between coal and renewable energy sources in Kazakhstan may become shale gas” – the Minister of Environmental Protection, Nurlan Kapparov.

Ceremonies of signing of memorandum between: KAZCENTR ELECTRO PROVOD and FRAUSHER Sensor Techniques; the United Nations World Tourism Organization and the Ministry of Industry and New Technologies; Economic and Social Commission for Asia and the Pacific Countries and the Secretariat of Integration Committee of the Eurasian Economic Community.

Take part in discussion of this events on the platform of G-Global: http://group-global.org/session?lang=en

Contact information:
Aizhan Murzahmetova
Email: a.murzakhmetova @ astanaforum.org
tel: +8(7172)571795

SOURCE “Eurasian Economic Club of Scientists” Association

NEW YORK, May 24, 2013 /PRNewswire/ – United Airlines announced that, effective today, the airline is the only U.S. carrier offering 180-degree flat-bed seats and personal on-demand entertainment in premium cabins on every scheduled, long-haul international flight from the New York area.

United has outfitted 182 international aircraft with all-new United Global First and United BusinessFirst cabins. With more than 450 daily departures to more than 150 cities, United offers the most nonstop flights to the most destinations around the world from New York‘s three major airports – Newark Liberty, Kennedy and LaGuardia. United also offers the most flat-bed seats and the most extra-legroom economy seats from New York‘s three major airports.

“We continue to invest in every aspect of the customer experience – online, in our airports and in the air,” said Jeff Foland , United’s executive vice president – marketing, technology and strategy. “With more robust online and mobile tools, more modern terminal facilities and lounges, on-demand entertainment and a growing number of our aircraft with global satellite Wi-Fi, we are working to ensure we remain the New York region’s best choice for air travel.”

United in New York/Newark

United operates a major global gateway hub at Newark Liberty, the most convenient airline hub to Wall Street and Times Square and the only New York-area airport served directly by regional and national rail lines. Customers departing from or arriving at Newark Liberty can transit between the Newark Liberty International Airport rail station and United’s terminals within minutes. The rail station offers immediate access to New York Pennsylvania Station, New Jersey and southern New York State.

This week, United detailed $150 million in plans to redesign the airline’s Terminal C check-in facilities at Newark Liberty, install new flight-information displays, deploy a new checked-baggage screening system and complete construction of a widebody maintenance hangar.

Inflight Experience

In addition to its terminal investments and improvements to its long-haul international aircraft, United is upgrading its transcontinental p.s. Premium Service aircraft that fly from New York Kennedy to San Francisco and Los Angeles. The Boeing 757 aircraft will, once retrofitted, offer flat-bed premium cabin seats and Wi-Fi and personal on-demand entertainment available throughout the aircraft. The fourth p.s. aircraft to be retrofitted enters service in June. The airline anticipates completing the entire p.s. fleet by year-end.

United is also outfitting aircraft with satellite Wi-Fi, offering inflight connectivity on long-haul international flights. The airline expects to have more than 200 aircraft with satellite Wi-Fi before the end of the year.

This month, United deployed the 200th aircraft with live television, giving United the world’s largest fleet of aircraft equipped with live television.

United.com and Mobile Technology

United offers customers the convenience of booking and managing travel online and via mobile devices. The airline offers the most saver-style award seats for frequent flyers among the largest U.S. global carriers, according to the 4th annual Switchfly Reward Seat Availability Survey published this month by IdeaWorksCompany.

Additionally, the airline offers customers the ability to book and manage travel on the four largest mobile operating systems.

About United

United Airlines and United Express operate an average of 5,446 flights a day to more than 370 airports across six continents. In 2012, United and United Express carried more passenger traffic than any other airline in the world and operated nearly two million flights carrying 140 million customers. United is investing in upgrading its onboard products and now offers more flat-bed seats in its premium cabins and more extra-legroom economy-class seating than any airline in North America. In 2013, United became the first U.S.-based international carrier to offer satellite-based Wi-Fi on long-haul overseas routes. The airline also features DIRECTV® on 200 aircraft, offering customers more live television access than any other airline in the world. United operates nearly 700 mainline aircraft and has made large-scale investments in its fleet. In 2013, United will continue to modernize its fleet by taking delivery of more than two dozen new Boeing aircraft. The company expanded its industry-leading global route network in 2012, launching nine new international and 18 new domestic routes. Business Traveler magazine awarded United Best Airline for North American Travel for 2012, and readers of Global Traveler magazine have voted United’s MileagePlus program the best frequent flyer program for nine consecutive years. According to the 4th annual Switchfly Reward Seat Availability Survey published by IdeaWorksCompany in May 2013, United has the most saver-style award-seat availability among the largest U.S. global airlines. United is a founding member of Star Alliance , which provides service to 194 countries via 27 member airlines. More than 85,000 United employees reside in every U.S. state and in countries around the world. For more information, visit united.com or follow United on Twitter and Facebook. The common stock of United’s parent, United Continental Holdings, Inc., is traded on the NYSE under the symbol UAL.

(Logo: http://photos.prnewswire.com/prnh/20130404/MM89155LOGO)

SOURCE United Airlines

RELATED LINKS
http://www.united.com

NEW YORK, May 24, 2013 /PRNewswire/ — In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the United States Exchange Act, Echo Pharma Acquisition Limited (“Royalty Pharma“) today announced acceptance levels its original offer for Elan Corporation (NYSE: ELN).

Background

On 2 May 2013, Echo Pharma Acquisition Limited (“Royalty Pharma“) made an offer for the entire of the issued and to be issued share capital of Elan Corporation, plc (“Elan“) (the “Original Offer“). 

On 20 May 2013, Royalty Pharma announced the terms of a revision to the Original Offer (the “Increased Offer“). The Increased Offer was made on 23 May 2013 and is an all cash offer of US$12.50 per Elan Share (including each Elan Share represented by an Elan ADS). The full terms of, and conditions to, the Increased Offer and the procedure for acceptance are set out in the revised offer document despatched by Royalty Pharma on 23 May 2013 (the “Revised Offer Document“). 

A reference in this announcement to the “Offer” means the Original Offer (including where the context so requires, any subsequent revision, variation, extension or renewal of the Original Offer, including in connection with the Increased Offer). Capitalised terms used but not defined in this announcement shall have the meaning given to them in the Revised Offer Document.

Royalty Pharma is making this announcement in accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act.

Level of Acceptances

As at 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on 23 May 2013 (being the date the Original Offer was revised), Royalty Pharma had received valid acceptances of the Offer (which had not been withdrawn) from Elan Stockholders in respect of 67,814 Elan Shares (including Elan Shares represented by Elan ADSs). These acceptances represent, at the applicable time: (1) approximately 0.01% of the Maximum Elan Shares Affected (as defined in the Revised Offer Document) and which may be counted towards the satisfaction of the Acceptance Condition to the Offer (as set out in paragraph (a) of Part A of Appendix I to the Revised Offer Document); and (2) approximately 0.01% of the issued share capital of Elan.

So far as Royalty Pharma is aware, none of these acceptances have been received from persons acting in concert with Royalty Pharma.

The Extended Closing Date of the Increased Offer

The Increased Offer, which is subject to the terms and conditions set out in the Revised Offer Document, will remain open for acceptance until, the “Extended Closing Date” which will be 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on 6 June 2013, being the date fixed by Royalty Pharma as the extended closing date of the Increased Offer (or such later time(s) and/or date(s) as Royalty Pharma may: (i) with the consent of the Irish Takeover Panel (to the extent required) or in accordance with the Irish Takeover Rules; and (ii) subject to the US tender offer rules (subject to certain exemptive relief which has been granted in respect of the Offer by the SEC) determine as the closing date for acceptance of the Increased Offer, in which case the term “Extended Closing Date” shall mean the latest time and date which the Increased Offer, as extended by Royalty Pharma, may be accepted or, if earlier, the date on which the Increased Offer becomes or is declared unconditional in all respects).

Interests in relevant securities

As at the close of business on 22 May 2013, being the last practicable date prior to this announcement, J.P. Morgan and persons controlling, controlled by or under the same control as J.P. Morgan (except in any such case, in the capacity of an exempt market marker, and excluding any exempt fund manager) were interested in 65 Elan ADSs.

As at the close of business on 22 May 2013, being the last practicable date prior to this announcement, BofA Merrill Lynch and persons controlling, controlled by or under the same control as BofA Merrill Lynch (except in any such case, in the capacity of an exempt market marker, and excluding any exempt fund manager) were interested in 439,332 Elan ADSs and 749,900 derivatives referenced to Elan ADSs.

As at the close of business on 22 May 2013, being the last practicable date prior to this announcement, BofA Merrill Lynch and persons controlling, controlled by or under the same control as BofA Merrill Lynch (except in any such case, in the capacity of an exempt market marker, and excluding any exempt fund manager) held short positions in 759,312 Elan ADSs.

As at the close of business on 22 May 2013, being the last practicable date prior to this announcement, Locus Global I, LP, an entity controlled by Rory Riggs , a director of RP Management (Ireland) Limited was interested in 772 Elan ADSs.

Save as disclosed above, as at the close of business on 22 May 2013, being the last practicable date prior to this announcement, none of Royalty Pharma, RP Management or any person acting in concert with Royalty Pharma or RP Management had any interest, or held any short position, in any relevant securities of Elan.

About Royalty Pharma

RP Management is the investment manager to entities investing in royalty interests in marketed and late stage biopharmaceutical products, with a portfolio of royalty interests in 38 approved and marketed products (including Abbott’s Humira®, Johnson and Johnson’s Remicade®, Merck’s Januvia®, Gilead’s Atripla®, Truvada®, and Emtriva®, Pfizer’s Lyrica®, Amgen’s Neupogen® and Neulasta®, and Genentech’s Rituxan®) and two products pending approval. Such product portfolio is well-diversified across biopharmaceutical products and treatment areas and consists of stable and long-dated assets and includes royalties on 8 of the top 20 selling pharmaceutical and biotech drugs by expected worldwide 2016 sales[1], and 9 products with over US$1 billion in annual sales. These entities have a longer than fifteen year history of providing value to holders of royalty interests, including a US$400 million purchase of 80% of Memorial Sloan-Kettering Cancer Center’s Neupogen®/ Neulasta® royalty, a US$525 million joint acquisition with Gilead Sciences of Emory University‘s emtricitabine royalty interest, a US$650 million purchase of New York University‘s Remicade® royalty, a US$700 million acquisition of AstraZeneca’s Humira® royalty, a US$700 million purchase of a portion of Northwestern University‘s Lyrica® royalty, a US$609 million acquisition of Astellas Pharma’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes including Januvia® and Janumet®, and most recently a US$761 million purchase of a portion of an interest in Biogen’s recently approved Tecfidera (formerly BG-12) for the treatment of multiple sclerosis held by the former shareholders of Fumapharm AG.

Responsibility Statements

The directors of Royalty Pharma accept responsibility for the information contained in this announcement, save that the only responsibility accepted by the directors of Royalty Pharma in respect of the information in this announcement relating to Elan, the Elan Group, the Board of Elan and the persons connected with them, which has been compiled from published sources, has been to ensure that such information has been correctly and fairly reproduced or presented (and no steps have been taken by the directors of Royalty Pharma to verify this information). To the best of the knowledge and belief of the directors of Royalty Pharma (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

The managing member of RP Management accepts responsibility for the information contained in this announcement, save that the only responsibility accepted by the managing member of RP Management in respect of the information in this announcement relating to Elan, the Elan Group, the Board of Elan and the persons connected with them, which has been compiled from published sources, has been to ensure that such information has been correctly and fairly reproduced or presented (and no steps have been taken by the managing member of RP Management to verify this information). To the best of the knowledge and belief of the managing member of RP Management (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which he accepts responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Other

J.P. Morgan, together with its affiliate J.P. Morgan Cazenove (which is authorised and regulated by the Financial Conduct Authority in the United Kingdom), is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to clients of J.P. Morgan or its affiliates, or for providing advice in relation to the Increased Offer or any other matters referred to in this announcement.

BofA Merrill Lynch, together with its affiliate Merrill Lynch International (which is authorised and regulated by the Financial Conduct Authority in the United Kingdom), is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to clients of BofA Merrill Lynch or its affiliates or for providing advice in relation to the Increased Offer or any other matters referred to in this announcement.

Groton Partners is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to its clients or for providing advice in relation to the Increased Offer or any other matters referred to in this announcement.

Forward-looking Statements

This announcement may include certain “forward looking statements” with respect to the business, strategy and plans of Royalty Pharma and its expectations relating to the Increased Offer and Elan’s future financial condition and performance. Statements that are not historical facts, including statements about Elan or Royalty Pharma or Royalty Pharma’s belief and expectation, are forward looking statements. Words such as “believes”, “anticipates”, “estimates”, “expects”, “intends”, “aims”, “potential”, “will”, “would”, “could”, “considered”, “likely”, and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur.

Examples of such forward looking statements include (but are not limited to) statements about expected benefits and risks associated with the Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Additional Information

This announcement is not a substitute for the Revised Offer Document and the Revised Acceptance Documents or any other document that Royalty Pharma has filed and may file with the Securities and Exchange Commission (“SEC”) (including the Original Offer Document) in connection with the Offer.  ELAN STOCKHOLDERS ARE URGED TO READ ANY SUCH DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE INCREASED OFFER.  Any such documents will be available free of charge through the website maintained by the SEC at www.sec.gov or by directing a request to any of the persons listed above.

The Offer is and will be made in the United States pursuant to the US Exchange Act subject to certain exemptive relief which has been granted in respect of the Offer by the SEC and otherwise in accordance with the requirements of the Irish Takeover Rules.  Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, offer timetable, settlement procedures and timing of payments that may be different from those typically applicable under U.S. domestic tender offer procedures and law.  In addition, the Original Offer Document, the Revised Offer Document and any other documents relating to the Offer have been or will be prepared in accordance with the Irish Takeover Rules and Irish disclosure requirements, format and style, all of which may differ from those in the United States.

Elan is incorporated under the laws of Ireland.  Some of the directors of Elan are resident in countries other than the United States.  As a result, it may not be possible for United States holders of Elan Stock to effect service of process within the United States upon Elan or such directors of Elan or to enforce against any of them judgements of the United States predicated upon the civil liability provisions of the federal securities laws of the United States.  It may not be possible to sue Elan or its officers or directors in a non-US court for violations of US securities laws.  In addition, US holders of Elan Stock should be aware that, if Royalty Pharma elects to proceed pursuant to a scheme of arrangement (as described in the Original Offer Document and to be described in the Revised Offer Document), the federal securities laws of the United States may not be applicable.

---

[1] Based on Evaluate Pharma estimates for 2016.

SOURCE Royalty Pharma

- Le soluzioni basate su SuperServer® GRID K1 e K2 supportano fino a 7.680 utenti concorrenti per 42U SuperRack®

SAN JOSE, California, 24 Maggio 2013 /PRNewswire/ — Super Micro Computer, Inc. (NASDAQ: SMCI), leader mondiale di server a elevate prestazioni ed elevata efficienza, soluzioni tecnologiche per lo storage, e green computing, ha annunciato oggi che le piattaforme Supermicro SuperServer® integrano le schede NVIDIA GRID K1 e K2 per il supporto delle infrastrutture desktop virtuali (VDI) nelle grandi aziende. Queste soluzioni VDI possono essere distribuite in cluster ad alta densità per servire pool di utenti su grande scala. Le piattaforme di Supermicro basate su tecnologia NVIDIA GRID sono totalmente convalidate per fornire un’esperienza utente con la migliore capacità di risposta e supportare la virtualizzazione con soluzioni software di Citrix®, VMware® e Microsoft. Le schede NVIDIA GRID K2 sono ottimizzate per l’esecuzione di compiti di tipo grafico e con uso intensivo di 3D nelle applicazioni Adobe®, Autodesk® e SolidWorks®, le schede NVIDIA GRID K1 offrono VDI a elevata densità per lavoratori della conoscenza. OEM e fornitori di servizi che desiderano sfruttare questa nuova potenza di calcolo virtualizzata per poter distribuire soluzioni estremamente scalabili su configurazioni server per aziende di grande dimensioni Supermicro 1U, 2U, 4U/Tower, e 4U FatTwin™ NVIDIA GRID.

(Foto: http://photos.prnewswire.com/prnh/20130523/AQ19727-INFO)

“Supermicro fornisce le migliori soluzioni server per le infrastrutture virtualizzate in termini di prestazioni per watt, per dollaro e il supporto NVIDIA GRID è un ampliamento naturale delle nostre piattaforme,” ha dichiarato Charles Liang , Presidente e Amministratore Delegato di Supermicro. “Di fatto, il nostro successo nello sviluppare la più ricca scelta di soluzioni HPC basate su GPU ha portato a questa innovazione per applicazioni virtualizzate destinate a grandi aziende. I clienti che cercano il percorso più efficace ed efficiente per avere piattaforme scalabili per grandi aziende non devono cercare al di là di Supermicro per avere una selezione dedicata di soluzioni ottimizzate NVIDIA GRID.”

“Grazie a NVIDIA GRID, la grafica con accelerazione hardware è disponibile per gli utenti di virtualizzazione su desktop, offrendo così finalmente le prestazioni e la compatibilità che sono stati lo standard per i PC per decenni,” ha dichiarato Jeff Brown , vice presidente e direttore generale dell’unità aziendale GRID presso NVIDIA. “Con la vasta scelta di soluzioni server certificate di Supermicro, i professionisti IT hanno la flessibilità necessaria per distribuire nelle loro organizzazioni piattaforme desktop virtualizzate ottimizzate.”

Piattaforme server Supermicro che supportano NVIDIA GRID:

• 1U GRID SuperServer® (SYS-1027GR-TSF)
• 1U GRID SuperServer® (AS-1022GG-TF)
• 2U GRID SuperServer® (SYS-2027GR-TRF)
• 4U/Tower GRID SuperServer® (SYS-7047GR-TPRF)
• 4U/Tower GRID SuperServer® (AS-4022G-6F)
• 4U GRID FatTwin™ (SYS-F627G3-FT+)

Visitare www.supermicro.com/GPU per avere maggiori informazioni sulla gamma completa di Supermicro di soluzioni basate su GPU o visitare la linea completa di Supermicro di server a elevate prestazione, elevata efficienza e soluzioni per lo storage sul sito www.supermicro.com.

Seguire Supermicro su Facebook e Twitter per ricevere le notizie e gli aggiornamenti più recenti.

Informazioni su Super Micro Computer, Inc.

Supermicro® (NASDAQ: SMCI), innovatore leader di tecnologie di server ad alta efficienza e a prestazioni elevate è un primario fornitore di server avanzati Building Block Solutions® per centri dati, Cloud Computing, infrastruttura IT di grandi aziende, Hadoop/Big Data, HPC e sistemi integrati in tutto il mondo. Supermicro Supermicro è impegnata nel rispetto dell’ambiente con l’iniziativa “We Keep IT Green(R)” fornendo ai clienti le soluzioni più efficienti ed ecologiche disponibili sul mercato.

Supermicro, FatTwin, SuperServer, Building Block Solutions and We Keep IT Green sono marchi e/o marchi registrati di Super Micro Computer, Inc.

NVIDIA, il logo NVIDIA e GRID sono marchi e/o marchi registrati di NVIDIA Corporation negli Stati Uniti e in altre nazioni

Tutti gli altri marchi, nomi e marchi commerciali sono di proprietà dei rispettivi proprietari.

SMCI-F

SOURCE Super Micro Computer, Inc.

RELATED LINKS
http://www.supermicro.com

NEW YORK, May 24, 2013 /PRNewswire-USNewswire/ — Multiple sclerosis is a life altering disease that affects each person in a unique and different way.   More than 2.1 million people worldwide live with MS, which is why demonstrating the power and importance of the global MS movement is critical on World MS Day – May 29.

(Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO)

World MS Day is worldwide collaborative awareness campaign taking place in more than 40 countries.  The campaign builds understanding of multiple sclerosis, an often disabling disease of the central nervous system which interrupts the flow of information within the brain and between the brain and the body.  MS is the most common neurological disease affecting young adults. Its hallmark is unpredictability and its symptoms range from numbness and tingling to blindness and paralysis.  

Central to the campaign are multi-media awareness efforts stretching around the globe that illustrate what living with MS means, including the opportunity for people affected by MS , especially young adults who are benefitting from current breakthrough treatments, to share the mottos that help guide their daily lives.  For news and pictures of World MS Day activities, see  www.worldmsday.org.    

Leveraging the messaging of the global World MS Day campaign, the National MS Society is also encouraging those who would like to help create a world free of MS to visit www.nationalMSsociety.org  so they can find out how to become part of the global movement and discover what mottos guide people living with MS. They can also add their own mottos if they like.

Other creative efforts supporting and building on World MS Day are:

• To leverage engagement opportunities, Society chapters across the U.S. will be interviewing young adults impacted by MS and collecting photos and video footage which they will post online to inspire and activate people to Join the MS Movement and help create a world free of multiple sclerosis.
• The Society has just launched the funding of 65 new cutting-edge research projects as part of its holistic research strategy that will commit over $48 million to research in 2013 aimed at stopping MS, restoring function and ending MS forever.
• A Live twitter Chat will be jointly hosted on May 28^th,1-2 pm ET by the Society and Everyday Health.com. The hashtag is #HealthTalk.  It will focus on the latest in research and treatment options and feature Dr. Bruce Bebo , Associate.VP for Discovery Research at the National MS Society and Dr. Gavin Giovannoni , who is affiliated with the Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery in London, as well as several people with MS – Breea Renee , the US Ambassador for World MS Day; David Lyons , a noted body builder and Trevis Gleason , Everyday Health’s Life with MS blogger  http://www.everydayhealth.com/healthtalk/-healthtalk-multiple-sclerosis-awareness.aspx?
• A Live Webcast sponsored by the Society will follow on June 11th, 3-4 pm ET and focus on Living Well with MS: Lifestyle, Diet, and Complementary Therapies. It will feature Dr. Brenda Banwell , Division Chief, Neurology, Professor of Pediatrics, Children’s Hospital of Philadelphia; Dr. Allen Bowling , Medical Director of the MS Program at the Colorado Neurological Institute; Dr. Albert Lo , Associate Professor of Neurology and Epidemiology, Brown University and Director of the MS Clinic Providence VA Medical Center; and Dr. Timothy Coetzee , Chief Research Officer at the Society.
• In recognition of World MS Day  and the Society’s partnership with Pour le Monde 100% natural eau de parfums , on May 29th for each bottle of the ENVISION fragrance purchased, the Society will receive 15% of the purchase price back to support research and program services. http://www.pourlemondeparfums.com/
• MSConnection.org, the Society’s online community site, which is an important resource for people affected by MS who would like to connect, share stories, gain insights, and support one another, will be adding several new and exciting features to enhance these goals. Beginning in June, when visitors come to MSconnection.org, they will find at their fingertips customized recommendations based on the information shared on their profiles, online support groups with experienced support group leaders, live chat rooms, enhanced opportunities to search for and connect with people based on the topics that interest them, inspiring stories of people defying MS, tips and breaking research news from MS experts, and much more!
• Whether you volunteer, bike, walk, advocate, educate, support – every action is a way of moving us closer to a world without multiple sclerosis and shows your commitment to the MS movement so please visit www.nationalMSsociety.org to see how you can get involved and make every connection count.

About Multiple Sclerosis
Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain and between the brain and the body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with more than twice as many women as men being diagnosed with the disease. MS affects more than 2.1 million worldwide.

About the National Multiple Sclerosis Society
The Society addresses the challenges of each person affected by MS.  To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people living with MS and their families move forward with their lives.

In 2012 alone, through its national office and 50-state network of chapters, the Society devoted $121.9 million to its programs and services that assisted more than one million people. To move us closer to a world free of MS, the Society also invested $43.3 million to support over 350 new and ongoing research projects around the world. The Society is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org

SOURCE National Multiple Sclerosis Society

RELATED LINKS
http://www.nmss.org